Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mutational Landscape and Environmental Effects in Bladder Cancer
Takuji Hayashi, Kazutoshi Fujita, Yujiro Hayashi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6072-6072
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Jonathan E. Rosenberg, Se Hoon Park, Vadim Kozlov, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 1, pp. 43-53
Open Access | Times Cited: 38
Biological differences underlying sex and gender disparities in bladder cancer: current synopsis and future directions
Bhavisha Doshi, Sarah R. Athans, Anna Woloszynska‐Read
Oncogenesis (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 25
Proteomic analysis of urinary and tissue‐exudative extracellular vesicles to discover novel bladder cancer biomarkers
Eisuke Tomiyama, Kyosuke Matsuzaki, Kazutoshi Fujita, et al.
Cancer Science (2021) Vol. 112, Iss. 5, pp. 2033-2045
Open Access | Times Cited: 51
Preclinical models of bladder cancer: BBN and beyond
David Matye, Juliann Leak, Benjamin L. Woolbright, et al.
Nature Reviews Urology (2024) Vol. 21, Iss. 12, pp. 723-734
Closed Access | Times Cited: 7
Tumor Heterogeneity and Consequences for Bladder Cancer Treatment
Étienne Lavallée, John P. Sfakianos, David J. Mulholland
Cancers (2021) Vol. 13, Iss. 21, pp. 5297-5297
Open Access | Times Cited: 33
Amyloids in bladder cancer hijack cancer-related proteins and are positive correlated to tumor stage
Diego Alem, César X. García-Laviña, Francisco Garagorry, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer
Shayan Smani, J.B. Dubois, Kai Sun Zhao, et al.
Current Oncology Reports (2025)
Closed Access
Advances in therapeutic agents targeting quiescent cancer cells
Wan Najbah Nik Nabil, Zhichao Xi, Mengfan Liu, et al.
Acta Materia Medica (2022) Vol. 1, Iss. 1
Open Access | Times Cited: 21
Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity
Xiao Yang, Jiancheng Lv, Zijian Zhou, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 18
Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
Marjorie Besançon, Typhaine Gris, France‐Hélène Joncas, et al.
European Urology Open Science (2022) Vol. 43, pp. 35-44
Open Access | Times Cited: 16
Current and Emerging Strategies to Treat Urothelial Carcinoma
Berkha Rani, James J. Ignatz-Hoover, Priyanka S. Rana, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4886-4886
Open Access | Times Cited: 9
A Comprehensive Bioinformatics Analysis of Notch Pathways in Bladder Cancer
Chuan Zhang, Mandy Berndt‐Paetz, Jochen Neuhaus
Cancers (2021) Vol. 13, Iss. 12, pp. 3089-3089
Open Access | Times Cited: 18
The biological impacts of CEBPD on urothelial carcinoma development and progression
Ti‐Chun Chan, Yow‐Ling Shiue, Chien‐Feng Li
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma
Yujiro Hayashi, Kazutoshi Fujita, George J. Netto, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 16
Accurate Detection of Urothelial Bladder Cancer Using Targeted Deep Sequencing of Urine DNA
Dongin Lee, Wookjae Lee, Hwang‐Phill Kim, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2868-2868
Open Access | Times Cited: 6
Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing
Fangming Wang, Xiying Dong, Feiya Yang, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 10
Bladder cancer
Richard L. Pullen
Nursing (2024) Vol. 54, Iss. 4, pp. 27-39
Open Access | Times Cited: 1
Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non–muscle-invasive bladder cancer using multi-layered –omics studies
Murat Akand, Tatjana Jatsenko, Tim Muilwijk, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Chronic exposure to microcystin-leucine-arginine induces epithelial hyperplasia and inflammation in the mouse bladder
Shaoru Zhang, Weidong Wu, Yi Peng, et al.
Ecotoxicology and Environmental Safety (2022) Vol. 244, pp. 114033-114033
Closed Access | Times Cited: 7
AKT1 and PIK3CA activating mutations in Moroccan bladder cancer patients´ biopsies and matched urine.
Hajar El Ahanidi, Meryem El Azzouzi, Housna Arrouchi, et al.
PubMed (2022) Vol. 41, pp. 59-59
Closed Access | Times Cited: 6
Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective
Pratap Singh, Anand Rotte, Anthony A. Golsorkhi, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 6, pp. 533-548
Open Access | Times Cited: 3
Toward urinary cell-free DNA-based treatment of urothelial carcinoma: a narrative review
Yujiro Hayashi, Kazutoshi Fujita
Translational Andrology and Urology (2021) Vol. 10, Iss. 4, pp. 1865-1877
Open Access | Times Cited: 8
Gasdermin D: A potential mediator and prognostic marker of bladder cancer
Randa El-Gamal, Mona Abdel Rahim, Mohamed El‐Sherbiny, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 5
Immunometabolism in the Bladder Cancer Microenvironment
Mohammad Javad Fattahi, Mohammad Reza Haghshenas, Abbas Ghaderi
Endocrine Metabolic & Immune Disorders - Drug Targets (2022) Vol. 22, Iss. 12, pp. 1201-1216
Closed Access | Times Cited: 4
Molecular mechanism of di-n-butyl phthalate promotion of bladder cancer development
Enhui Li, Bai‐Hui Xu, Haibin Wei, et al.
Toxicology in Vitro (2022) Vol. 86, pp. 105508-105508
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top